These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16317809)

  • 1. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.
    Dixon BS; Beck GJ; Dember LM; Depner TA; Gassman JJ; Greene T; Himmelfarb J; Hunsicker LG; Kaufman JS; Lawson JH; Meyers CM; Middleton JP; Radeva M; Schwab SJ; Whiting JF; Feldman HI;
    Clin Trials; 2005; 2(5):400-12. PubMed ID: 16317809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
    Dember LM; Kaufman JS; Beck GJ; Dixon BS; Gassman JJ; Greene T; Himmelfarb J; Hunsicker LG; Kusek JW; Lawson JH; Middleton JP; Radeva M; Schwab SJ; Whiting JF; Feldman HI;
    Clin Trials; 2005; 2(5):413-22. PubMed ID: 16317810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dipyridamole plus aspirin on hemodialysis graft patency.
    Dixon BS; Beck GJ; Vazquez MA; Greenberg A; Delmez JA; Allon M; Dember LM; Himmelfarb J; Gassman JJ; Greene T; Radeva MK; Davidson IJ; Ikizler TA; Braden GL; Fenves AZ; Kaufman JS; Cotton JR; Martin KJ; McNeil JW; Rahman A; Lawson JH; Whiting JF; Hu B; Meyers CM; Kusek JW; Feldman HI;
    N Engl J Med; 2009 May; 360(21):2191-201. PubMed ID: 19458364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    Tanner NC; Da Silva A
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD002786. PubMed ID: 26184395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing arteriovenous shunt failure in hemodialysis patients: a population-based cohort study.
    Fan PY; Lee CC; Liu SH; Li IJ; Weng CH; Tu KH; Hsieh MY; Kuo CF; Chang TY; Tian YC; Yang CW; Wu HH
    J Thromb Haemost; 2019 Jan; 17(1):77-87. PubMed ID: 30472783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.
    Nee R; Parker AL; Little DJ; Yuan CM; Himmelfarb J; Lowe SR; Abbott KC
    Clin Nephrol; 2014 Jan; 81(1):38-51. PubMed ID: 24161074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of aspirin associates with longer primary patency of hemodialysis grafts.
    Dixon BS; Beck GJ; Dember LM; Vazquez MA; Greenberg A; Delmez JA; Allon M; Himmelfarb J; Hu B; Greene T; Radeva MK; Davidson IJ; Ikizler TA; Braden GL; Lawson JH; Cotton JR; Kusek JW; Feldman HI;
    J Am Soc Nephrol; 2011 Apr; 22(4):773-81. PubMed ID: 21415156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study.
    Lok CE; Allon M; Donnelly S; Dorval M; Hemmelgarn B; Moist L; Oliver MJ; Tonelli M; Stanley K
    Clin Trials; 2007; 4(4):357-67. PubMed ID: 17848497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study.
    Conte MS; Nugent HM; Gaccione P; Guleria I; Roy-Chaudhury P; Lawson JH
    J Vasc Surg; 2009 Dec; 50(6):1359-68.e1. PubMed ID: 19958986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial.
    Irish AB; Viecelli AK; Hawley CM; Hooi LS; Pascoe EM; Paul-Brent PA; Badve SV; Mori TA; Cass A; Kerr PG; Voss D; Ong LM; Polkinghorne KR;
    JAMA Intern Med; 2017 Feb; 177(2):184-193. PubMed ID: 28055065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Saran R; Dykstra DM; Wolfe RA; Gillespie B; Held PJ; Young EW;
    Am J Kidney Dis; 2002 Dec; 40(6):1255-63. PubMed ID: 12460045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
    Irish A; Dogra G; Mori T; Beller E; Heritier S; Hawley C; Kerr P; Robertson A; Rosman J; Paul-Brent PA; Starfield M; Polkinghorne K; Cass A
    BMC Nephrol; 2009 Jan; 10():1. PubMed ID: 19159453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.
    Viecelli AK; Pascoe E; Polkinghorne KR; Hawley C; Paul-Brent PA; Badve SV; Cass A; Heritier S; Kerr PG; Mori TA; Robertson A; Seong HL; Irish AB;
    BMC Nephrol; 2015 Jun; 16():89. PubMed ID: 26116581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy and vascular-access patency.
    Lok CE
    N Engl J Med; 2009 May; 360(21):2240-2. PubMed ID: 19458370
    [No Abstract]   [Full Text] [Related]  

  • 16. Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Ravani P; Quinn RR; Oliver MJ; Karsanji DJ; James MT; MacRae JM; Palmer SC; Strippoli GF
    Am J Kidney Dis; 2016 Mar; 67(3):446-60. PubMed ID: 26776537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintaining vascular access: the management of hemodialysis arteriovenous grafts.
    Schild AF
    J Vasc Access; 2010; 11(2):92-9. PubMed ID: 20155717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
    Lenz TL; Hilleman DE
    Ann Pharmacother; 2000 Nov; 34(11):1283-90. PubMed ID: 11098344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
    Serebruany VL; Malinin AI; Sane DC; Jilma B; Takserman A; Atar D; Hennekens CH
    Eur J Pharmacol; 2004 Sep; 499(3):315-24. PubMed ID: 15381054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access placement.
    Jackson RS; Sidawy AN; Amdur RL; Khetarpal A; Macsata RA
    J Vasc Surg; 2011 Dec; 54(6):1706-12. PubMed ID: 21840155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.